The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).
 
Patricia LoRusso
Stock and Other Ownership Interests - BAKX Therapeutics
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Salarius Pharmaceuticals; Scenic Biotech; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Mrinal M. Gounder
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron; Springworks Therapeutics; TYME
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Ono Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Manish R. Patel
Leadership - ION Pharma
Honoraria - Janssen Oncology
Consulting or Advisory Role - Olema Pharmaceuticals
Research Funding - Accutar Biotech (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); BioTheryX (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); Compugen (Inst); Compugen (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Jacobio (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); MabSpace Biosciences (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NGM Biopharmaceuticals (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Nurix (Inst); nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); Puretech (Inst); PureTech (Inst); PureTech (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Seven and Eight Biopharmaceuticals (Inst); Silicon Therapeutics (Inst); Step Pharma (Inst); Syndax (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vigeo Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - Bayer; Lilly; Pfizer; Sanofi
Speakers' Bureau - Bayer; Lilly
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Junxian Geng
Employment - Boehringer Ingelheim
Stock and Other Ownership Interests - IO Biotech; Moderna Therapeutics
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Reinhard Sailer
Employment - Boehringer Ingelheim
Stock and Other Ownership Interests - Bayer; Pieris Pharmaceuticals; Replimune
 
Yuefen Tang
Employment - Boehringer Ingelheim France
 
Girish Jayadeva
Employment - Boehringer Ingelheim
 
Patrick Schöffski
Consulting or Advisory Role - Adcendo; Amryt Pharma; Avacta Life Sciences; Biolumina; Boehringer Ingelheim; Boxer Capital; Cogent Biosciences; Curio Science; Deciphera; Eisai; Ellipses Pharma; Exelixis; Genmab; LLX Solutions; Medpace; Merck; Moleculin Biotech; PharmaMar; Regeneron; Sanofi; SERVIER; SQZ Biotechnology; Studiecentrum voor Kernenergie (SCK CEN); Transgene; UCB
Research Funding - Adcendo (Inst); CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genmab (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst)